WSAAI 2018: 56th Annual Scientific Session

January 21, 2018 to January 25, 2018

Didactic lectures allow the speakers to provide evidence based medical recommendations, updates and expert opinion in a efficient manner.

Target Audience

Practicing allergists, physicians and allied health professionals.

Learning Objectives

  • Describe common and uncommon clinical presentations of immunological or allergic disease
  • Assess the benefits and limitations of medication classes presently available to treat immunological or allergic diseases.
  • Evaluate the evidence base on new and emerging therapies for immunological or allergic disease.
  • Discuss recent advances in the understanding of pathophysiology of immunological or allergic disease.
Additional information

Disclosure Policy and Disclosures

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.


The individuals listed below disclose the following financial relationships:

Cem Akin, MD, PhD – Speaker

Consultant – Novartis, Blueprint Medicines


Leonard B. Bacharier, MD – Speaker

Speaker – AstraZeneca, Boehringer Ingelheim, Novartis

Consultant – DBV Technologies, GlaxoSmithKline, Merck, Novartis, Regeneron, TEVA, Vectura, Circassia

DSMB Member – DBV Technologies

Contracted research – Vectura


Larry Borish, MD – Speaker

*Contracted research – Cumberland Pharmaceuticals

Consultant – Allakos

Compensated DSMB – PluriStem

*All funds go to the University of Virginia


Mario Castro, MD, MPH, FCCP – Speaker

Speaker – Boehringer Ingelheim, AstraZeneca, Boston Scientific, Genentech, TEVA

Principal Investigator – Boehringer Ingelheim, Chiesi, Sanofi-Aventis, Vectura, ALA, NIH, PCORI

Consultant – Nuvaira, Aviragen, Genentech, Neutronic, Sanofi-Aventis, TEVA, Theravance, Vectura

Author – Elsevier

Co-Investigator – NIH, PCORI


Thomas A. Fleisher, MD, FAAAAI, FACAAI – Speaker

Co-editor – Elsevier Ltd.



Jon M. Hanifin, MD – Speaker

Consultant – AbbVie, GlaxoSmithKline, Medimetriks, Menlo Therapeutics


Rohit Katial, MD – Speaker

Employee – GlaxoSmithKline


Robert A. Wood, MD – Speaker

Investigator – Astellas, Aimmune, DBV, HAL-Allergy


Warner Carr, MD – Planner, Moderator, Reviewer

Speaker – Regeneron/Sanofi Genzyme, Boehinger Ingelheim, TEVA

Consultant – Glenmark Pharmaceuticals, TEVA, Meda/Mylan


Travis Miller, MD – Planner, Moderator

Speaker – AstraZeneca, Genentech, Mylan

Consultant – AstraZeneca, Boston Scientific, Mylan

Research – TEVA


Amy Wagelie-Steffen, MD – Planner, Moderator

Speaker – Genentech, Regeneron, Sanofi

Author – Genentech


Jennifer Namazy, MD – Planner, Moderator

Advisory Board – Genentech


Matthew Bowdish, MD – Planner

Research – Genentech, TEVA

Advisory Board – GSK


The following have no relevant financial relationships to disclose:


Amy Klion, MD – Speaker

Mark T. O’Hollaren – Speaker

Karol Anderson – Planner

Rene Anderson-Cowell, MD – Planner

David Elkayam, MD – Planner

Steve Machtinger, MD – Planner


Course summary
Available credit: 
  • 21.00 AMA PRA Category 1 Credit™
  • 21.00 Attendance
Course opens: 
Course expires: 
Event starts: 
01/21/2018 - 3:00pm CST
Event ends: 
01/25/2018 - 5:40pm CST


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Western Society of Allergy, Asthma & Immunology.  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 21 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.





The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 21.00 AMA PRA Category 1 Credit™
  • 21.00 Attendance
Please login or create an account to take this course.